Does the media favor ADV or MXCT?

In the previous week, MaxCyte had 2 more articles in the media than Advantage Solutions. MarketBeat recorded 4 mentions for MaxCyte and 2 mentions for Advantage Solutions. Advantage Solutions' average media sentiment score of 1.66 beat MaxCyte's score of 1.43 indicating that Advantage Solutions is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Advantage Solutions 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive MaxCyte 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NEXN or MXCT?

In the previous week, Nexxen International had 8 more articles in the media than MaxCyte. MarketBeat recorded 12 mentions for Nexxen International and 4 mentions for MaxCyte. MaxCyte's average media sentiment score of 1.43 beat Nexxen International's score of 0.47 indicating that MaxCyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nexxen International 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MaxCyte 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BWMN or MXCT?

In the previous week, MaxCyte had 2 more articles in the media than Bowman Consulting Group. MarketBeat recorded 4 mentions for MaxCyte and 2 mentions for Bowman Consulting Group. MaxCyte's average media sentiment score of 1.43 beat Bowman Consulting Group's score of 0.93 indicating that MaxCyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bowman Consulting Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MaxCyte 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, NRC or MXCT?

National Research has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio National Research $137.39M 3.61 $11.60M $0.39 55.97 MaxCyte $33.03M 4.48 -$44.63M -$0.37 N/A

Does the media favor NRC or MXCT?

In the previous week, MaxCyte had 2 more articles in the media than National Research. MarketBeat recorded 4 mentions for MaxCyte and 2 mentions for National Research. MaxCyte's average media sentiment score of 1.43 beat National Research's score of 1.30 indicating that MaxCyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment National Research 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MaxCyte 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, YEXT or MXCT?

Yext has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Yext, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Yext $446.58M 1.17 $37.87M $0.07 74.61 MaxCyte $33.03M 4.48 -$44.63M -$0.37 N/A

Is YEXT or MXCT more profitable?

Yext has a net margin of 8.93% compared to MaxCyte's net margin of -121.16%. Yext's return on equity of 43.47% beat MaxCyte's return on equity. Company Net Margins Return on Equity Return on Assets Yext 8.93% 43.47% 9.28% MaxCyte -121.16% -20.03% -17.14%

Does the media prefer YEXT or MXCT?

In the previous week, Yext had 1 more articles in the media than MaxCyte. MarketBeat recorded 5 mentions for Yext and 4 mentions for MaxCyte. MaxCyte's average media sentiment score of 1.43 beat Yext's score of 0.92 indicating that MaxCyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Yext 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MaxCyte 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MaxCyte (MXCT) Competitors

$1.38 +0.05 (+3.76%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$1.38 +0.01 (+0.36%)

As of 07/13/2026 06:51 PM Eastern

Compare

MXCT vs. ADV, NEXN, BWMN, NRC, and YEXT

Should you buy MaxCyte stock or one of its competitors? MarketBeat compares MaxCyte with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MaxCyte include Advantage Solutions (ADV), Nexxen International (NEXN), Bowman Consulting Group (BWMN), National Research (NRC), and Yext (YEXT). These companies are all part of the "business services" industry.

How does MaxCyte compare to Advantage Solutions?

Advantage Solutions (NASDAQ:ADV) and MaxCyte (NASDAQ:MXCT) are both small-cap business services companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

MaxCyte has lower revenue, but higher earnings than Advantage Solutions. MaxCyte is trading at a lower price-to-earnings ratio than Advantage Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Advantage Solutions	$3.54B	0.15	-$227.74M	-$18.74	N/A
MaxCyte	$33.03M	4.48	-$44.63M	-$0.37	N/A

Advantage Solutions has a net margin of -6.78% compared to MaxCyte's net margin of -121.16%. MaxCyte's return on equity of -20.03% beat Advantage Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Advantage Solutions	-6.78%	-37.22%	-7.93%
MaxCyte	-121.16%	-20.03%	-17.14%

Advantage Solutions has a beta of 2.18, suggesting that its share price is 118% more volatile than the broader market. Comparatively, MaxCyte has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market.

Advantage Solutions currently has a consensus price target of $34.38, suggesting a potential downside of 16.53%. MaxCyte has a consensus price target of $5.50, suggesting a potential upside of 298.55%. Given MaxCyte's stronger consensus rating and higher probable upside, analysts plainly believe MaxCyte is more favorable than Advantage Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Advantage Solutions	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MaxCyte	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, MaxCyte had 2 more articles in the media than Advantage Solutions. MarketBeat recorded 4 mentions for MaxCyte and 2 mentions for Advantage Solutions. Advantage Solutions' average media sentiment score of 1.66 beat MaxCyte's score of 1.43 indicating that Advantage Solutions is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Advantage Solutions	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
MaxCyte	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

49.8% of Advantage Solutions shares are held by institutional investors. Comparatively, 68.8% of MaxCyte shares are held by institutional investors. 9.7% of Advantage Solutions shares are held by insiders. Comparatively, 4.1% of MaxCyte shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

MaxCyte beats Advantage Solutions on 9 of the 16 factors compared between the two stocks.

How does MaxCyte compare to Nexxen International?

Nexxen International (NASDAQ:NEXN) and MaxCyte (NASDAQ:MXCT) are both small-cap business services companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

In the previous week, Nexxen International had 8 more articles in the media than MaxCyte. MarketBeat recorded 12 mentions for Nexxen International and 4 mentions for MaxCyte. MaxCyte's average media sentiment score of 1.43 beat Nexxen International's score of 0.47 indicating that MaxCyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nexxen International	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MaxCyte	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nexxen International has a beta of 1.62, suggesting that its share price is 62% more volatile than the broader market. Comparatively, MaxCyte has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market.

Nexxen International presently has a consensus target price of $11.61, suggesting a potential upside of 17.64%. MaxCyte has a consensus target price of $5.50, suggesting a potential upside of 298.55%. Given MaxCyte's higher possible upside, analysts plainly believe MaxCyte is more favorable than Nexxen International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexxen International	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
MaxCyte	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Nexxen International has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Nexxen International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexxen International	$364.78M	1.52	$25.04M	$0.30	32.90
MaxCyte	$33.03M	4.48	-$44.63M	-$0.37	N/A

54.2% of Nexxen International shares are held by institutional investors. Comparatively, 68.8% of MaxCyte shares are held by institutional investors. 4.1% of MaxCyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Nexxen International has a net margin of 4.85% compared to MaxCyte's net margin of -121.16%. Nexxen International's return on equity of 7.78% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexxen International	4.85%	7.78%	4.94%
MaxCyte	-121.16%	-20.03%	-17.14%

Summary

Nexxen International beats MaxCyte on 11 of the 16 factors compared between the two stocks.

How does MaxCyte compare to Bowman Consulting Group?

Bowman Consulting Group (NASDAQ:BWMN) and MaxCyte (NASDAQ:MXCT) are both small-cap business services companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Bowman Consulting Group has a beta of 1.34, meaning that its stock price is 34% more volatile than the broader market. Comparatively, MaxCyte has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market.

In the previous week, MaxCyte had 2 more articles in the media than Bowman Consulting Group. MarketBeat recorded 4 mentions for MaxCyte and 2 mentions for Bowman Consulting Group. MaxCyte's average media sentiment score of 1.43 beat Bowman Consulting Group's score of 0.93 indicating that MaxCyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bowman Consulting Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MaxCyte	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bowman Consulting Group currently has a consensus price target of $47.50, suggesting a potential upside of 75.47%. MaxCyte has a consensus price target of $5.50, suggesting a potential upside of 298.55%. Given MaxCyte's higher possible upside, analysts clearly believe MaxCyte is more favorable than Bowman Consulting Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bowman Consulting Group	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
MaxCyte	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

63.2% of Bowman Consulting Group shares are held by institutional investors. Comparatively, 68.8% of MaxCyte shares are held by institutional investors. 17.5% of Bowman Consulting Group shares are held by insiders. Comparatively, 4.1% of MaxCyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Bowman Consulting Group has a net margin of 2.02% compared to MaxCyte's net margin of -121.16%. Bowman Consulting Group's return on equity of 3.98% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bowman Consulting Group	2.02%	3.98%	1.84%
MaxCyte	-121.16%	-20.03%	-17.14%

Bowman Consulting Group has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Bowman Consulting Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bowman Consulting Group	$490.02M	0.97	$12.85M	$0.60	45.12
MaxCyte	$33.03M	4.48	-$44.63M	-$0.37	N/A

Summary

Bowman Consulting Group beats MaxCyte on 10 of the 16 factors compared between the two stocks.

How does MaxCyte compare to National Research?

National Research (NASDAQ:NRC) and MaxCyte (NASDAQ:MXCT) are both small-cap business services companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

National Research has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, MaxCyte has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market.

47.3% of National Research shares are held by institutional investors. Comparatively, 68.8% of MaxCyte shares are held by institutional investors. 9.2% of National Research shares are held by company insiders. Comparatively, 4.1% of MaxCyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

National Research presently has a consensus target price of $23.00, suggesting a potential upside of 5.36%. MaxCyte has a consensus target price of $5.50, suggesting a potential upside of 298.55%. Given MaxCyte's higher probable upside, analysts clearly believe MaxCyte is more favorable than National Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
National Research	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
MaxCyte	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

National Research has a net margin of 6.52% compared to MaxCyte's net margin of -121.16%. National Research's return on equity of 122.73% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
National Research	6.52%	122.73%	14.18%
MaxCyte	-121.16%	-20.03%	-17.14%

National Research has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
National Research	$137.39M	3.61	$11.60M	$0.39	55.97
MaxCyte	$33.03M	4.48	-$44.63M	-$0.37	N/A

In the previous week, MaxCyte had 2 more articles in the media than National Research. MarketBeat recorded 4 mentions for MaxCyte and 2 mentions for National Research. MaxCyte's average media sentiment score of 1.43 beat National Research's score of 1.30 indicating that MaxCyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
National Research	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MaxCyte	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

National Research beats MaxCyte on 9 of the 16 factors compared between the two stocks.

How does MaxCyte compare to Yext?

Yext (NYSE:YEXT) and MaxCyte (NASDAQ:MXCT) are both small-cap business services companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

In the previous week, Yext had 1 more articles in the media than MaxCyte. MarketBeat recorded 5 mentions for Yext and 4 mentions for MaxCyte. MaxCyte's average media sentiment score of 1.43 beat Yext's score of 0.92 indicating that MaxCyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Yext	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MaxCyte	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

71.0% of Yext shares are owned by institutional investors. Comparatively, 68.8% of MaxCyte shares are owned by institutional investors. 7.8% of Yext shares are owned by insiders. Comparatively, 4.1% of MaxCyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Yext has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, MaxCyte has a beta of 1.47, indicating that its stock price is 47% more volatile than the broader market.

Yext presently has a consensus price target of $7.50, suggesting a potential upside of 43.60%. MaxCyte has a consensus price target of $5.50, suggesting a potential upside of 298.55%. Given MaxCyte's stronger consensus rating and higher probable upside, analysts plainly believe MaxCyte is more favorable than Yext.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yext	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
MaxCyte	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Yext has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Yext, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yext	$446.58M	1.17	$37.87M	$0.07	74.61
MaxCyte	$33.03M	4.48	-$44.63M	-$0.37	N/A

Yext has a net margin of 8.93% compared to MaxCyte's net margin of -121.16%. Yext's return on equity of 43.47% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yext	8.93%	43.47%	9.28%
MaxCyte	-121.16%	-20.03%	-17.14%

Summary

Yext beats MaxCyte on 10 of the 15 factors compared between the two stocks.

Get MaxCyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MXCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MXCT vs. The Competition

Export

Metric	MaxCyte	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$142.47M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-3.73	20.85	27.13	24.26
Price / Sales	4.48	314.01	589.11	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	0.86	8.49	10.77	6.29
Net Income	-$44.63M	$23.83M	$3.58B	$330.66M
7 Day Performance	6.98%	-3.56%	-2.10%	-1.32%
1 Month Performance	23.21%	6.31%	3.29%	-0.64%
1 Year Performance	-38.39%	48.30%	26.34%	19.08%

MaxCyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MXCT MaxCyte	3.7034 of 5 stars	$1.38 +3.8%	$5.50 +298.6%	-37.8%	$142.47M	$33.03M	N/A	80	News Coverage Positive News Short Interest Decrease
ADV Advantage Solutions	3.0129 of 5 stars	$40.02 0.0%	$34.38 -14.1%	+7.0%	$532.21M	$3.54B	N/A	73,000	News Coverage Positive News
NEXN Nexxen International	4.4297 of 5 stars	$9.39 +0.8%	$11.17 +18.9%	+1.3%	$524.57M	$364.78M	31.30	895
BWMN Bowman Consulting Group	4.2889 of 5 stars	$28.37 -3.6%	$47.50 +67.4%	-11.1%	$515.43M	$490.02M	47.28	2,300
NRC National Research	1.7343 of 5 stars	$22.77 +1.2%	$23.00 +1.0%	+36.8%	$511.79M	$137.39M	58.38	490

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MXCT) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MaxCyte (MXCT) Competitors

MXCT vs. ADV, NEXN, BWMN, NRC, and YEXT

How does MaxCyte compare to Advantage Solutions?

Summary

How does MaxCyte compare to Nexxen International?

Summary

How does MaxCyte compare to Bowman Consulting Group?

Summary

How does MaxCyte compare to National Research?

Summary

How does MaxCyte compare to Yext?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MXCT vs. The Competition

MaxCyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MaxCyte (MXCT) Competitors

MXCT vs. ADV, NEXN, BWMN, NRC, and YEXT

How does MaxCyte compare to Advantage Solutions?

Which has preferable earnings & valuation, ADV or MXCT?

Is ADV or MXCT more profitable?

Which has more volatility & risk, ADV or MXCT?

Do analysts prefer ADV or MXCT?

Does the media favor ADV or MXCT?

Do institutionals & insiders have more ownership in ADV or MXCT?

Summary

How does MaxCyte compare to Nexxen International?

Does the media favor NEXN or MXCT?

Which has more risk and volatility, NEXN or MXCT?

Do analysts prefer NEXN or MXCT?

Which has stronger valuation & earnings, NEXN or MXCT?

Do insiders & institutionals have more ownership in NEXN or MXCT?

Is NEXN or MXCT more profitable?

Summary

How does MaxCyte compare to Bowman Consulting Group?

Which has more risk and volatility, BWMN or MXCT?

Does the media prefer BWMN or MXCT?

Do analysts recommend BWMN or MXCT?

Do insiders and institutionals have more ownership in BWMN or MXCT?

Is BWMN or MXCT more profitable?

Which has better earnings & valuation, BWMN or MXCT?

Summary

How does MaxCyte compare to National Research?

Which has more volatility and risk, NRC or MXCT?

Do insiders & institutionals have more ownership in NRC or MXCT?

Do analysts recommend NRC or MXCT?

Is NRC or MXCT more profitable?

Which has higher valuation & earnings, NRC or MXCT?

Does the media favor NRC or MXCT?

Summary

How does MaxCyte compare to Yext?

Does the media prefer YEXT or MXCT?

Do insiders and institutionals have more ownership in YEXT or MXCT?

Which has more volatility and risk, YEXT or MXCT?

Do analysts rate YEXT or MXCT?

Which has higher earnings & valuation, YEXT or MXCT?

Is YEXT or MXCT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MXCT vs. The Competition

MaxCyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools